Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05736835 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
A Phase 2 study of COVID-19, sponsored by CyanVac.
- Active
- Registry status
- Phase 2
- Development phase
- 227
- Enrollment target
- 10
- Study locations
NCT05736835: Active Phase 2 study of COVID-19, sponsored by CyanVac.
NCT05736835 is a Phase 2 study of COVID-19 that is active but no longer recruiting, run by CyanVac. The registered enrollment target is 227 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05736835, a Phase 2 study of COVID-19, is active but no longer recruiting, sponsored by CyanVac.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 227 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this trial is to evaluate immunogenicity and safety of CVXGA administered as a single intranasal dose against SARS-CoV-2 S-protein in participants. The trial will enroll up to 400 healthy participants, age 18-80 years.
Primary Outcome
Percentage of subjects overall reporting: Local reactions for up to 7 days following vaccination (Day 1-8); Systemic events for up to 7 days following vaccination (Day 1-8); Adverse events (AEs) from Day 1 to 29; Serious AEs from Day 1 to 181; AESI from day 1 to 181; Comparison of the percentage of subjects reporting the events listed above compared with percentage of subjects in the placebo group
Conditions Studied
Interventions
- BIOLOGICAL CVXGA
Study Locations (10)
New York
- University of Rochester - Rochester
- Velocity Clinical Research - Vestal
California
- Velocity Clinical Research - San Diego
Idaho
- Velocity Clinical Research - Boise
Iowa
- Velocity Clinical Research - Sioux City
Maryland
- Velocity Clinical Research - Rockville
Nebraska
- Velocity Clinical Research - Omaha
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Rhode Island
- Velocity Clinical Research - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2023-06-30 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
What the registry record for NCT05736835 still lists
NCT05736835 is an interventional study that assigns participants to a tested intervention. The registered 227 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which CVXGA is the first listed.
NCT05736835 lists 10 locations in 9 states (New York, California, Idaho).
Frequently Asked Questions
What is clinical trial NCT05736835 about?
NCT05736835 is a clinical study titled "A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults". The purpose of this trial is to evaluate immunogenicity and safety of CVXGA administered as a single intranasal dose against SARS-CoV-2 S-protein in participants. The trial will enroll up to 400 healthy participants, age 18-80 years.
What is the current status of trial NCT05736835?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2023-06-30. Estimated completion is 2028-06-30.
What conditions does trial NCT05736835 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT05736835?
The interventions under investigation include: CVXGA (BIOLOGICAL).
Who is sponsoring clinical trial NCT05736835?
This trial is sponsored by CyanVac, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05736835 being conducted?
This trial has 10 study locations across California, Idaho, Iowa, Maryland, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05736835's enrollment target sits among peer trials
227 155th of 298 higher than 143 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04751409 · 227 participants · Phase 2
Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities
- NCT05742360 · 227 participants
Effect of CPAP on Blood Pressure in Excessively Sleepy Obstructive Sleep Apnea Subtype
- NCT05890352 · 227 participants · Phase 2
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI